



CASE LD0339 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Elliott Korsen
Type or print name

Signature

10/20/03
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

BHIDE ET AL.

APPLICATION NO: 10/622,280

FILED: JULY 18, 2003

FOR: PROCESS FOR PREPARING CERTAIN PYRROLOTRIAZINE
COMPOUNDS

MAIL STOP: DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.


Applicants also call the Examiner's attention to the following U.S. Applications, copies of which are available upon request:

<u>Application No.</u>	<u>Filing Date</u>	<u>BMS Docket No.</u>	<u>Status</u>
10/289,010	11/06/02	QA237A CIP 1	Pending
09/753,829	05/18/00	LD170 NP	Pending
10/294,281	11/14/02	LD280 NP	Pending
10/633,997	08/04/03	LD299 NP	Pending
10/623,171	07/18/03	LD310 NP	Pending
10/420,399	04/22/03	QA267 NP	Pending
10/420,445	04/22/03	QA270 NP	Pending
10/440,864	05/19/03	QA272 NP	Pending

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-4741


Elliott Kersen
Attorney for Applicants
Reg. No. 32,705

Date: October 20, 2003

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.
LD0339 NP
APPLICATION NO.
10/622,280
APPLICANT
BHIDE ET AL.
FILING DATE
JULY 18, 2003

Group



Do not leave blank sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	US2003/0069244 A1	4/10/03	Leftheris, et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 00/71129	11/30/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Fan et al., Trend Pharmacol. Sci. Vol. 16, pgs. 57-66 (1995)
	AS	Folkman, Nature Medicine, Vol. 1, pgs. 27-31 (1995)
	AT	Cullinan-Bove et al., Endocrinology, Vol. 133, pgs. 829-837 (1993)

EXAMINER

DATE CONSIDERED


*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
LD0339 NP
APPLICATION NO.
10/622,280
APPLICANT
BHIIE ET AL.
FILING DATE
JULY 18, 2003

Group



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	SA	Spencer et al., Cancer and Metastasis Reviews, Vol. 12, pgs. 303-324 (1993)
	AB	DeVries et al., Science, Vol. 255, pgs. 989-991 (1992)
	AC	Terman et al., Biochem. Biophys. Res. Comm., Vol. 187, pgs. 1579-1586 (1992)
	AD	Jakeman et al., Endocrinology, Vol. 133, pgs. 848-859 (1993)
	AE	Kolch et al., Breast Cancer Research and Treatment, Vol. 36, pgs. 139-155 (1995)
	AF	Connolly et al., J. Biol. Chem., Vol. 264, pgs. 20017-20024 (1989)
	AG	
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.